Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study

Phase 3positiveLunsumioPositive

AI Analysis

Summary

Genentech announced that Lunsumio-based regimen significantly improved progression-free survival in follicular lymphoma patients in the Phase III CELESTIMO study. The positive trial data represents a potential advancement in the treatment of this lymphoma subtype.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Significantly improved progression-free survival

Importance:7/10

Sentiment:

0.80

Phase_3OncologyLymphomaClinical_Data

Related Companies

$RHHBY

Read the original article

Published by yahoo_finance on September 17, 2026 5:00 AM

Read Original